PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2020 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Sat - Aug 22      Sun - Aug 23      Mon - Aug 24      Tue - Aug 25   

MONDAY, AUGUST 24

7:00 - 7:45 AM
SATELLITE SYMPOSIUM
JANSSEN BREAKFAST SYMPOSIA: EVIDENCE-BASED APPROACH TO ANTICOAGULATION THERAPY FOR DVT/PE
Chicago Ballroom 7

8:00 - 9:00 AM
BASIC SCIENCE
NEW INSIGHTS ON MECHANISMS
Chair/Organizer: Shannon Meeks , Rodney Camire
Chicago Ballroom 10


8:00

ADVANCES IN UNDERSTANDING THE COFACTOR FUNCTIONS OF FACTOR V AND FACTOR VIII
Rodney Camire. University of Pennsylvania/Children's Hospital of Philadelphia


8:20

UNDERSTANDING THE CLOT FROM STUDIES OF FIBRIN AND FACTOR XIII
JW Weisel. University of Pennsylvania


8:40

UPDATE ON THE INTERPLAY BETWEEN COAGULATION AND COMPLEMENT SYSTEMS
Edward Conway. University of British Columbia Centre for Blood Research

8:00 - 9:00 AM
HEMOSTASIS
NEW STRATEGIES IN HEMOPHILIA THERAPY
Chair/Organizer: Kathleen Van Gordon, Christine Sabapathy
Sheraton Ballroom 5


8:00

CHALLENGING BLEEDING EVENTS IN PATIENTS ON NOVEL HEMOPHILIA THERAPIES
Glaivy Batsuli.


8:20

TOLERANCE IN THE AGE OF NON-FACTOR REPLACEMENT THERAPY
Shannon Meeks. Emory University/Children's Healthcare of Atlanta


8:40

HOW NEW THERAPIES ARE IMPACTING HEMOPHILIA TREATMENT CENTERS
Jim Munn. Michigan Medicine

8:00 - 9:00 AM
THROMBOSIS / LABORATORY
STARTING AND STOPPING DOACS
Chair/Organizer: Arthur Allen, Pall Onunderson
Sheraton Ballroom 1


8:00

PLANNED INTERRUPTION OF DOAC THERAPY
James Douketis. McMaster University


8:20

EMERGENCY REVERSAL OF DOAC THERAPY: CURRENT EVIDENCE ON BEST APPROACHES
Deb Siegal. McMaster University


8:40

LABORATORY SUPPORT FOR PATIENTS ON DOAC THERAPY: CHALLENGES TO CHECKING FOR DRUG AND MEASURING LEVELS
Adam Cuker. University of Pennsylvania

9:00 - 10:00 AM
SHORT TALKS
BASIC SCIENCE OF THROMBOSIS/ANTICOAGULATION
Chicago Ballroom 10


EXTRACELLULAR VESICLES DERIVED FROM RED BLOOD CELLS ACTIVATE MICROVASCULAR ENDOTHELIAL CELLS AND RESULT IN RED BLOOD CELL ADHESION IN SICKLE CELL DISEASE
Ran An1, Yuncheng Man1, Jane A. Little2, Umut A. Gurkan1. 1Case Western Reserve University, Cleveland, OH, USA. 2The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA


COMBINATION OF HEPARIN AND A FX/FXA APTAMER TO REDUCE THROMBIN GENERATION IN MODELS OF CARDIOPULMONARY BYPASS
Charlene V. Chabata1, 2, James W. Frederiksen2, Ruwan Gunaratne3, Bruce A. Sullenger1, 2. 1Duke University, Department of Pharmacology and Cancer Biology, Durham, NC, USA. 2Duke University, Department of Surgery, Durham, NC, USA. 3Stanford University, School of Medicine, Palo Alto, CA, USA


DIFFERENTIAL NEUTRALIZATION OF APIXABAN, BETRIXABAN, EDOXABAN, AND RIVAROXABAN BY ANDEXANET ALFA AS MEASURED BY WHOLE BLOOD THROMBOELASTOGRAPHIC ANALYSIS
Siddharth Mehrotra1, Debra Hoppensteadt1, Walter Jeske1, Omer Iqbal1, Alfonso Tafur2, Bruce Lewis1, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA. 2Northshore Health Systems, Skokie, IL, USA


INHIBITORS AGAINST PROCOAGULANT AND ANTIFIBRINOLYTIC PROPERTIES OF EXTRACELLULAR NUCLEIC ACIDS
Sreeparna Vappala1, 2, 8, Manu Thomas Kalathottukaren1, 2, 8, Srinivas Abbina1, 2, 8, Chanel La1, 3, 8, Libin Abraham4, 8, Iren Constantinescu1, 2, 8, Charles A Haynes1, 5, 8, Edward M Conway1, 6, 8, Jayachandran N Kizhakkedathu1, 2, 3, 7, 8. 1Centre for Blood Researc, Vancouver, BC, Canada. 2Department of Pathology and Laboratory medicine, Vancouver, BC, Canada. 3Department of Chemistry, Vancouver, BC, Canada. 4Microbiology and Immunology, Vancouver, BC, Canada. 5Chemical a Biological Engineering, Vancouver, BC, Canada. 6Department of Medicine, Vancouver, BC, Canada. 7The School of Biomedical Engineering, Vancouver, BC, Canada. 8University of British Columbia, Vancouver, BC, Canada


BLEEDING DISORDER THERAPY
Chicago Ballroom 9


AN INTERNATIONAL MULTICENTER STUDY OF BEVACIZUMAB FOR BLEEDING IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: THE INHIBIT-BLEED STUDY
Hanny Al-Samkari1, 2, Raj S. Kasthuri3, Joseph G. Parambil4, Hasan A. Albitar5, Carolina Vazquez6, Marcelo M. Serra6, Sophie Dupuis-Girod7, Craig B. Wilsen8, Justin P. McWilliams8, Evan H. Fountain9, James R. Gossage9, Clifford R. Weiss10, Assaf Issachar11, Mary E. Meek12, Miles Conrad13, Vivek N. Iyer5. 1Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA. 2Harvard Medical School, Boston, MA, USA. 3Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA. 5Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA. 6Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. 7Centre de Reference pour la maladie de Rendu-Osler, Hospices Civils de Lyon, Lyon, France. 8Division of Interventional Radiology, Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 9Division of Pulmonary, Critical Care, and Sleep Medicine, Augusta University, Augusta, GA, Augusta, GA, USA. 10Russel H. Morgan Department of Radiology and Radiological Science, Division of Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 11Schneider Children, Tel Aviv, Israel. 12Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 13Department of Radiology, University of California San Francisco Medical Center, San Francisco, CA, USA


TREATMENT OF IMMUNE THROMBOCYTOPENIA WITH THE SPLEEN TYROSINE KINASE INHIBITOR FOSTAMATINIB: RESTORING HEMOSTATIC BALANCE WHILEAVOIDING A PROTHROMBOTIC STATE
Ivy Altomare1, Vadim Markovtsov2, Leslie Todd2, Dheepika Weerasinghe2, Robert P Numerof2, Sandra Tong2, Esteban Masuda2, James B Bussel3. 1Duke University School of Medicine, Durham, NC, USA. 2Rigel Pharmaceuticals, Inc, South SanFrancisco, CA, USA. 3New York Presbyterian Hosp. Weill Cornell Medical Center, New York, NY, USA


EFFICACY AND SAFETY OF SIMOCTOCOG ALFA IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HAEMOPHILIA A: FINAL RESULTS FROM THE NUPROTECT STUDY
Ri J Liesner1, Ellis J Neufeld2, on behalf of the NuProtect Study Group1. 1Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom. 2St. Jude Children, Memphis, TN, USA


USE OF EMICIZUMAB PROPHYLAXIS IN ADULT AND PEDIATRIC HEMOPHILIA A PATIENTS WITH AND WITHOUT INHIBITORS. SINGLE CENTER EXPERIENCE.
Natalie A. Montanez, Donna Oldfield, Stephanie Gustafson, Joanna Larson, Nidra I. Rodriguez, Neethu Menon, Deborah Brown, Miguel A. Escobar. University of Texas Health Science Center and Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA


LABORATORY 2
Chicago Ballroom 7


ORDER SET MODIFICATION PROMOTES EFFECTIVE LABORATORY TEST UTILIZATION IN THE DIAGNOSIS OFHIT
Michael Kimbrell, John Larson, Mikhail Akbashev. Emory University Department of Medicine, Atlanta, GA, USA


UNRELIABILITY OF ACTIVATED PARTIAL THROMBOPLASTIN TIME TO MONITOR BIVALIRUDIN THERAPY IN PEDIATRIC EXTRACORPOREAL LIFE SUPPORT
Vadim Kostousov1, 2, Karen Bruzdoski1, Lisa Hensch1, 2, Shiu-Ki Rocky Hui1, 2, Jun Teruya1, 2. 1Texas Children's Hospital, Houston, TX, USA. 2Baylor College of Medicine, Houston, TX, USA


SEROTONIN RELEASE ASSAY BY LIQUID MASS SPECTROMETRY: A COMPARATIVE LABORATORY METHODS STUDY
Rachel R Leger1, Jennifer A Faber1, Deepti M Warad1, Ravinder J Singh1, Jansen N Seheult2, Rajiv K Pruthi1, Dong Chen1. 1Mayo Clinic, Rochester, MN, USA. 2University of Pittsburgh Medical Center, Pittsburgh, PA, USA


CHROMOGENIC BETHESDA ASSAY PERFORMANCE IN HEMOPHILIA A PATIENTS WITH AND WITHOUT EMICIZUMAB
Connie H Miller1, Brian Boylan1, Amanda B Payne1, Jennifer Driggers1, Christopher J Bean1, HIRS Investigators2. 1Centers for Disease Control and Prevention, Atlanta, GA, USA. 2See appendix, HIRS United States


THROMBOSIS: DIAGNOSIS AND MANAGEMENT
Chicago Ballroom 6


ANALYSIS OF MANAGEMENT STRATEGIES FOLLOWING SLIGHTLY OUT OF RANGE INRS: WATCHFUL WAITING VS. ANY DOSE CHANGES
Hallie B. Remer1, Xiaokui Gu1, Brian Haymart1, Geoffrey D. Barnes1, Mona Ali2, Eva Kline-Rogers1, Tina Alexandris-Souphis1, Jay Kozlowski3, James B. Froehlich1, Vinay Shah4, Greg Krol4, Scott Kaatz4. 1University of Michigan, Ann Arbor, MI, USA. 2Beaumont Hospital, Royal Oak, MI, USA. 3Detroit Medical Center, Detroit, MI, USA. 4Henry Ford Health System, Detroit, MI, USA


OVERUTILIZATION OF VENOUS DOPPLER ULTRASONOGRAPHY TO DETECT DEEP VEIN THROMBOSIS IN INTENSIVE CARE UNITS
Sophie Samuel1, Thuy Nguyen1, James Beeson1, Thanh Dao1, Liang Zhu2, Louise D McCullough2. 1Memorial Hermann Medical Center, Houston, TX, USA. 2Univeristiy of Texas. McGovern Medical School, Houston, TX, USA


PREVALENCE, TRENDS, PREDICTORS AND OUTCOMES OF PORTAL VEIN THROMBOSIS IN HOSPITALIZED PANCREATIC CANCER PATIENTS: A NATIONWIDE INPATIENT SAMPLE DATABASE ANALYSIS FROM 1998-2016
Yu Zhao1, Hussam Alhasson1, Peng Cai2, Anas Saad3, Muneer Al-Husseini4. 1Department of Internal Medicine, Rochester Regional Health- Unity Hospital, Rochester, NY, USA. 2Department of Mathematical Sciences, Worcester Polytechnic Institute, Worcester, MA, USA. 3Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH, USA. 4Department of Internal Medicine, Ascension St John Hospital, Detroit, MI, USA

10:00 - 10:45 AM
POSTER SESSION
POSTERS/EXHIBITS
Exhibit Hall - Riverwalk AB


A2. PLATELET ACTIVATION AND BIOCHEMISTRY


163

APOLIPOPROTEIN A-IV IS AN ENDOGENOUS INHIBITOR OF THROMBOSIS: THE ROLES OF POLYMORPHISMS IN THE RISK OF CARDIOVASCULAR DISEASE
Si-Yang Yu1, 5, Daniel MacKeigan1, 2, 4, Miguel Neves1, 6, 7, Pingguo Chen1, 6, 7, Heyu Ni1-4, 6, 7. 1Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael, Toronto, ON, Canada. 2Department of Physiology, University of Toronto, Toronto, ON, Canada. 3Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 4Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 5Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, Changsha, China. 6Canadian Blood Services Centre for Innovation, Toronto, ON, Canada. 7Toronto Platelet Immunobiology Group, Toronto, ON, Canada


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


70

IMPACT OF FIRST LINE CORTICOSTEROID CHOICE ON PATIENT OUTCOMES IN ACUTE IMMUNE THROMBOCYTOPENIA
Sowda Ahmed, Maureen Laschen, Surbhi Shah. University of Minnesota Medical School, Minneapolis, MN, USA


71

EVALUATION OF LIGHT TRANSMISSION AGGREGOMETRY ON THE ROUTINE COAGULATION ANALYZER SYSMEX CS-2500
Safaa Mghinia1, 2, Yamna lanouari1, 2, mohamed nady1, karima mikou3, Bouchra Oukkache1, 2. 1Hematology Laboratory, CHU Ibn Rochd, Casablanca, Morocco. 2Hassan II University of Casablanca, Faculty of Medicine and Pharmacy, Casablanca, Morocco. 3Scientific Department, Megaflex sarl, Casablanca, Morocco


72

GAUCHER DISEASE SCREENING IN PATIENTS WITH THROMBOCYTOPENIA: A CROSS-SECTIONAL STUDY
Vidushi Swarup1, Nicole Veloce1, Aziz Jiwajee1, Hina R Hanif1, 4, Pauline Manuel1, Gloria Lim1-3, Rosane Nisenbaum5, Cyrus Hsia6, Michelle Sholzberg1-5. 1Hematology-Oncology Clinical Research Group, St. Michael's Hospital, Toronto, ON, Canada. 2Division of Hematology, Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada. 3Department of Medicine, University of Toronto, Toronto, ON, Canada. 4Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, Toronto, ON, Canada. 5Applied Health Research Centre, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada. 6Division of Hematology, Department of Medicine, London Health Sciences Centre, Toronto, ON, Canada


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


73

FIBRINOGEN COLUMBUS III: A NOVEL C. 963DEL FRAMESHIFT MUTATION IN FGG RESULTING IN HYPOFIBRINOGENEMIA AND BLEEDING
Eman Abdelghani1, Jennifer Dawson2, Kristin Zajo1, Michelle Hallam1, Riten Kumar 1. 1Division of Pediatric Hematology/Oncology/BMT, Nationwide Children, Columbus, OH, USA. 2Department of Structural Biology, St. Jude Children, Memphis, TN, USA


74

DIFFERENTIAL FIBRINOLYSIS DYNAMICS IN PERIPARTUM WOMEN BASED ON THE ROUTE OF DELIVERY
Maria Cristina Bravo, Thomas Orfeo, Kelley McLean, Ira Bernstein, Kathleen Brummel-Ziedins. University of Vermont, Burlington, VT, USA


75

COMBINED INHERITED AND ACQUIRED VON WILLEBRAND DISEASE: AN UNRECOGNIZED ENTITY
Maria DeSancho1, Kenneth Friedman2. 1Weill Cornell Medicine, New York, NY, USA. 2Blood Center of Wisconsin, Milwaukee, WI, USA


76

ANTI-TFPI ANTIBODY BAY 1093884: EARLY TERMINATION OF PHASE II STUDY DUE TO THROMBOSIS
Francesca Ferrante1, Sheila Ingham2, Marc Kunze3, Lisa A Michaels4. 1Bayer, Basel, Switzerland. 2Bayer, Sao Paulo, Brazil. 3Bayer, Berlin, Germany. 4Bayer, Whippany, NJ, USA


77

EFFICACY AND SAFETY OF “HALF-DOSE” DESMOPRESSIN FOR BLEEDING PROPHYLAXIS IN BLEEDING DISORDER PATIENTS UNDERGOING INVASIVE PROCEDURES
Fateeha Furqan1, Ronald Sham2, Peter Koiudes2. 1Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA. 2Department of Hematology and Oncology, Rochester General Hospital, Rochester, New York and the Mary M. Gooley Hemophilia Treatment Center of Rochester, Rochester, NY, USA


78

DIFFERENTIAL DIAGNOSIS FOR SWELLING OF THE SCALP IN INFANCY
Michelle M Hallam1, Amy L Dunn1, 2. 1Nationwide Children's Hospital, Columbus, OH, USA. 2Ohio State University Wexner Medical Center, Columbus, OH, USA


79

THE INTEGRATED ROLE OF C-REACTIVE PROTEIN, NITRIC OXIDE, DDIMER, MYELOPEROXIDASE, AND PLASMINOGEN ACTIVATOR INHIBITOR-1 IN THE PATHOGENESIS OF END STAGE RENAL DISEASE
Meriam Ben Hadj Tahar, Vinod Bansal, Emily Bontekoe, Alyssa Abrenica, Debra Hoppensteadt, Alek Druck, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


80

A RARE ETIOLOGY FOR WARFARIN SENSITIVITY IN A 28 YEAR OLD MALE
Natasha Pardy. Memorial University of Newfoundland, St. John's, NL, Canada


82

FAILURE OF MULTIPLE CONCURRENT ANTITHROMBOTIC AGENTS IN THE TREATMENT OF RECURRENT VENOUS THROMBOEMBOLISM IN A PATIENT WITH ELEVATED FACTOR VIII LEVELS
Bassil Said1, Mehul Patel2, Peter Kouides2. 1Rochester General Hospital, Department of Internal Medicine, Rochester, NY, USA. 2Rochester General Hospital, Lipson Cancer Center, Rochester, NY, USA


83

LABORATORY ASSESSMENT AND OPTIMIZATION OF A FVIII INHIBITOR ELISA KIT
Meera Sridharan, Katrina McGaffey, Julie Tange, Dong Chen , Rajiv Pruthi . Mayo Clinic, Rochester, MN, USA


84

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH HEMOPHILIA RECEIVING FITUSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC TARGETING ANTITHROMBIN FOR THE TREATMENT OF HEMOPHILIA
K. John Pasi1, Claude Negrier2, Margaret V. Ragni3, Pencho Georgiev4, Vasily Mamonov5, Toshko Lissitchkov 6, Kichou Salim7, Baisong Mei7, Shauna Andersson7. 1Royal London Hospital Haemophilia Centre, Barts and The London School of Medicine and Dentistry, London, United Kingdom. 2Unite d, Lyon, France. 3Department of Medicine and Hemophilia Center of Western Pennsylvania, University of Pittsburgh, Pittsburgh, PA, USA. 4University Multiprofile Hospital for Active Treatment Sveti Georgi and Medical University Plovdiv, Plovdiv, Bulgaria. 5National Research Center for Hematology, Moscow, Russia. 6 Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria. 7Sanofi, Cambridge, MA, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS


85

PHYSICAL ACTIVITY IN CHILDREN AT RISK OF POST-THROMBOTIC SYNDROME (PACT): A PILOT RANDOMIZED CONTROLLED TRIAL
Rida Hasan 1 , Maria Hanna1, Kendra Malone2, Song Zhang1, Ravi Sarode 1, Janna Journeycake3, Ayesha Zia1. 1University of Texas Southwestern Medical Center, Dallas, TX, USA. 2Children's Medical Center, Dallas, TX, USA. 3University of Oklahoma Health Science Center, Oklahoma City, OK, USA


86

UPREGULATION OF C-REACTIVE PROTEIN, PLASMINOGEN ACTIVATOR INHIBITOR-1, MMP-9, FIBRONECTIN, AND OSTEOPONTIN FOLLOWING TOTAL KNEE REPLACEMENT AND HIP REPLACEMENT SURGERY (TKA AND THA).
Maryanne Amour, Fakiha Siddiqui, Debra Hoppensteadt, Meriam Ben Hadj Tahar, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


87

VENOUS THROMBOEMBOLISM HOSPITALIZATION AND RELATED DEATH: ANALYSIS OF THE NATIONWIDE READMISSIONS DATABASE
Guillermo Tafur1, Alfonso Tafur2, Kambiez Zorriasateyn2, Cheong Lee2. 1Loyola University Medical Centerdi, Maywood, IL, USA. 2Northshore University health Systems, Skokie, IL, USA


88

TITLE: UPSHAW SCHULMAN SYNDROME IS A RARE MASQUERADER OF ATYPICAL HEMOLYTIC SYNDROME & THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN PREGNANCY RELATED THROMBOTIC MICROANGIOPATHY (P-TMA).
Fnu Kaweeta, Sandeep K Rajan. UTHSC, Memphis, TN, USA


A8. ANTITHROMBOTIC THERAPY


164

U. S. EMERGENCY DEPARTMENT VISITS FOR ORAL ANTICOAGULANT-RELATED BLEEDING, 2018
Andrew I. Geller1, Maribeth C. Lovegrove1, Daniel S. Budnitz1, Nadine Shehab2. 1Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2Lantana Consulting Group, contractor to the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


89

ENGAGING PATIENTS AND FAMILIES AT EMICIZUMAB INITIATION
Madolyn Hofstetter, Kelsey Smith, Susan U Lattimore. Oregon Health a Science University, Portland, OR, USA


90

SUCCESSFUL USE OF TISSUE PLASMINOGEN ACTIVATOR IN INFANTS WITH LIFE THREATENING THROMBOSIS ON EXTRACORPOREAL MEMBRANE OXYGENATION LIFE SUPPORT - A CASE REPORT
Dena R Wideman1 , Kristina A D'Agostino1. 2. 1Children's Mercy, Kansas City, MO, USA. 2University of Missouri Kansas City, Kansas City, MO, USA


91

DISEASE BURDEN AND HEALTHCARE UTILIZATION AMONG PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA EXPERIENCING CHRONIC PAIN: ANALYSES FROM A NATIONAL HEALTHCARE DATABASE
Samuel M. Silver 1, Angelika L. Erwin 2, Stephen Meninger3, Joseph Tkacz4, Virgina Noxon4, John J. Ko3. 1University of Michigan Medical Center, Ann Arbor, MI, USA. 2Cleveland Clinic, Cleveland, OH, USA. 3Alnylam Pharmaceuticals, Cambridge, MA, USA. 4IBM Watson Health, Bethesda, MD, USA

10:45 - 12:00 PM
PLENARY SESSION
PLENARY SESSION 2
Chair/Organizer: Peter Kouides, Christine Guelcher
Sheraton Ballroom


10:45

ANTICOAGULANT TARGETS: OVERVIEW OF CURRENT AND EMERGING THERAPIES
Jeff Weitz. McMaster University


11:10

THE IMPORTANCE OF PATIENT SAFETY CONSIDERATIONS: ANTICOAGULANTS PLACE IN THE PUBLIC HEALTH APPROACH TO MEDICATION SAFETY
Dan Budnitz. Centers for Disease Control and Prevention


11:35

MINIMIZING THROMBOTIC AND BLEEDING COMPLICATIONS IN THE SETTING OF SURGERY
PJ Devereaux. McMaster University

12:15 - 1:45 PM
SATELLITE SYMPOSIUM
CSL BEHRING LUNCH SYMPOSIA: A DIALOGUE ON ELEVATING PATIENT CARE FOR HEMOPHILIA B PATIENTS
Chicago Ballroom 6


NOVO NORDISK LUNCH SYMPOSIA:DOUBLE FEATURE: OBESITY IN HEMOPHILIA AND A NEW TREATMENT OPTION FOR HEMOPHILIA A
Chicago Ballroom 7

2:00 - 3:30 PM
THROMBOSIS
DTI USE
Chair/Organizer: Luis Meillon, Teresa Bordeaux
Sheraton Ballroom 1


2:00

DTI USE FOR ATYPICAL VTE (SPLANCHNIC BED, CEREBRAL VEIN THROMBOSIS) AND FOR HIT(T)
Rachel Rosovsky. Massachusetts General Hospital


2:30

DTI USE IN LVADS, ECMO, CARDIAC CATH
Jerrold Levy. Duke University School of Medicine


3:00

DTI USE IN PEDIATRICS
Shannon Carpenter. Children's Mercy Hospital

2:00 - 3:30 PM
HEMOSTASIS
EMERGING ISSUES IN BLEEDING DISORDERS
Chair/Organizer: Michelle Witkop, Shannon Jackson
Sheraton Ballroom 5


2:00

GENETIC TESTING FOR CONGENITAL THROMBOCYTOPENIA SYNDROMES
Brian Branchford. University of Colorado School of Medicine and Children's Hospital Colorado


2:30

TREATING PAIN IN PATIENTS WITH BLEEDING DISORDERS
Tyler Buckner. University of Colorado School of Medicine


3:00

ANTICOAGULATION FOR PATIENTS WITH BLEEDING DISORDERS (COVERS VTE PROPHY IN ORTHO PROCEDURES, RX OF AF, CAD IN BLEEDING DISORDER PTS AND PVT IN CIRRHOTICS)
Craig Kessler.

2:00 - 3:30 PM
LABORATORY / BASIC SCIENCE
UPDATE ON THROMBOTIC MICROANGIOPATHIES
Chair/Organizer: Charles Eby, Marian Rollins Raval
Chicago Ballroom 10


2:00

OVERVIEW ON THROMBOTIC THROMBOCYTOPENIC PURPURA INCLUDING THE IMPORTANCE OF ADAMTS13 ASSAYS FOR DIAGNOSIS
Sateesh Chonat.


2:30

NEW INSIGHTS ON THE CONTRIBUTIONS OF ADAMTS13 AND COMPLEMENT TO TTP PATHOGENESIS FROM EXPERIMENTAL MODELS
X. Long Zheng. The University of Alabama at Birmingham


3:00

CLINICAL AND LABORATORY CONSIDERATIONS FOR THE LONG TERM FOLLOWUP AND TREATMENT OF TTP
James George. University of Oklahoma Health Sciences Center

3:30 - 4:15 PM
POSTER SESSION
POSTERS/EXHIBITS
Exhibit Hall - Riverwalk AB


A8. ANTITHROMBOTIC THERAPY


93

IS THERE A NEED FOR ANTICOAGULATION FOR NEW-ONSET ATRIAL FIBRILLATION IN SEPSIS: A NARRATIVE REVIEW
Jesus Aibar1, 2, Sam Schulman2. 1Internal Medicine Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain. 2Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada


94

STANDARDIZATION OF DIRECT ORAL ANTICOAGULANT MANAGEMENT ACROSS A HEALTH SYSTEM
J Burdick, C Patterson, A Rose. University of Wisconsin Hospital and Clinics, Madison, WI, USA


95

GENOME-WIDE ANALYSIS OF WARFARIN PHARMACOGENOMICS IN PATIENTS FROM THE MIDDLE EAST AND NORTH AFRICAN REGION
Nihal El Rouby1, Mohamed Shahin2, Loulia Bader3, Hazem Elewa3. 1University of Cincinnati, Cincinnati, OH, USA. 2Pfizer Global Research, Groton, CT, USA. 3College of Pharmacy, Qatar University, Doha, Qatar


96

SULODEXIDE AS A PARENTERAL ANTICOAGULANT. A SUBSTITUTE FOR UNFRACTIONATED HEPARIN.
Bharathi Daravath1, Emily Bontekoe1, Ahmed Kouta1, Omer Iqbal1, Christopher Lattimer2, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA. 2Ealing Hospital, London United Kingdom


97

USP POTENCY EQUATED BOVINE MUCOSAL HEPARINS ARE COMPARABLE TO PORCINE MUCOSAL HEPARIN AND MAY BE INTERCHANGEABLE FOR ANTICOAGULATION.
Ahmed Kouta, Walter Jeske, Debra Hoppensteadt, Massimo Iacobelli, Omer Iqbal, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


98

SHEEP MUCOSAL HEPARIN AS A SUBSTITUTE FOR PORCINE MUCOSAL HEPARIN. A VIABLE OPTION TO ADDRESS THE POTENTIAL SHORTAGE CRISIS.
Ahmed Kouta1, Jawed Fareed1, Walter Jeske1, Debra Hoppensteadt1, Omer Iqbal1, Emily Bontekoe1, Massimo Iacobelli1, Yiming Yao2. 1Loyola University Medical Center, Maywood, IL, USA. 2Ronnsi Pharma, LTD, Suzhou China


99

WHOLE BLOOD ANTICOAGULANT EFFECTS OF SULODEXIDE AS MEASURED BY ACTIVATED CLOTTING TIME AND THEIR NEUTRALIZATION BY PROTAMINE SULFATE
Bharathi Daravath, Omer Iqbal, Debra Hoppensteadt, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


100

DIFFERENCES IN THE CLOT BASED AND AMIDOLYTIC ANTI-XA ASSAYS BETWEEN THE NEUTRALIZATION PROFILE OF APIXABAN, BETRIXABAN, EDOXABAN AND RIVAROXABAN
Fakiha Siddiqui1, Alfonso Tafur2, Debra Hoppensteadt1, Emily Bontekoe1, Walter Jeske1, Bruce Lewis1, Omer Iqbal1, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA. 2Northshore Health Systems, Skokie, IL, USA


101

ENHANCEMENT OF THROMBIN GENERATION IN LYMPHOMA COHORT BY ANDEXANET ALFA
Fakiha Siddiqui1, Emily Bontekoe1, Darko Antic2, Debra Hoppensteadt1, Grigoris Gerotziafas3, Ismail Elalamy3, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA. 2Clinical Center for Hematology, Belgrade Serbia. 3Tenon University Hospital, Paris France


102

EVALUATION OF ANTICOAGULATION PHARMACOTHERAPY AND CLINICAL OUTCOMES FOR ACUTE COMMUNITY-ACQUIRED VENOUS THROMBOEMBOLISM DIAGNOSED IN THE EMERGENCY DEPARTMENT
Thao N. Huynh1, Matthew E. Borrego1, Allison E. Burnett1, 2, Lisa R. Koselke2, Dusadee Sarangarm2, 3, Gregory C. Hadlock4. 1University of New Mexico College of Pharmacy, Albuquerque, NM, USA. 2University of New Mexico Hospital, Albuquerque, NM, USA. 3University of New Mexico Department of Emergency Medicine, Albuquerque, NM, USA. 4Presbyterian Healthcare Services, Albuquerque, NM, USA


103

CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS RECEIVING ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE FOR APIXABAN AND RIVAROXABAN ASSOCIATED MAJOR BLEEDING
John M. Koerber1, 3, Karissa Fritsch1, Janet L. Hoffman1, 3, Sean Mertz2, Nour Baalbaki1, Fatme Chehab3, Maureen A. Smythe1, 3. 1Beaumont Heatlh, Royal Oak, MI, USA. 2Cleveland Clinic, Cleveland, OH, USA. 3Wayne State University, Detroit, MI, USA


104

MANAGEMENT OF PULMONARY EMBOLISM AND CEREBRAL VENOUS SINUS THROMBOSIS IN CHILDREN WITH LEUKEMIA
Melanie Degliuomini1, 2, Victoria Cooley3, Elizabeth Mauer3, Linda Gerber3, Suchitra Acharya4, Nicole Kucine1. 1Weill Cornell Medicine, Department of Pediatrics, New York, NY, USA. 2Memorial Sloan Kettering Cancer Center, Department of Pediatrics, New York, NY, USA. 3Weill Cornell Medicine, Department of Healthcare Policy and Research, New York, NY, USA. 4Cohen Children's Medical Center, Northwell Health, New Hyde Park, NY, USA


105

THROMBOSIS AND ORAL ANTICOAGULATION IN PEDIATRICS PATIENTS: NOW IT IS POSSIBLE TO IMPROVE THE QUALITY OF LIFE AND CLINICAL SAFETY WITH THE “COAGULIN PROJECT”
RAFAEL MARTOS1, MARIA YUSTE1, ELENA GONZALEZ1, LAURA BERMEJO2, PILAR BELTRAN2, ADRIANA PASCUAL2, DELIA CORNEJO1, PILAR LLAMAS1, 2, 3. 1HOSPITAL GENERAL UNIVERSITARIO DE VILLALBA, MADRID, Spain. 2HOSPITAL UNIVERSITARIO INFANTA ELENA DE VALDEMORO, MADRID, Spain. 3HOSPITAL UNIVERSITARIO FUNDACION JIMENEZ DIAZ, MADRID, Spain


106

RETROSPECTIVE QUALITY ASSURANCE STUDY FOR POTENTIAL P2Y12 RECEPTOR INHIBITOR INTERFERENCE OF SEROTONIN RELEASE ASSAY (SRA) DETECTING ANTIBODIES ASSOCIATED WITH HEPARIN INDUCED THROMBOCYTOPENIA (HIT) IN PATIENT SPECIMENS
Morgan H. McCoy1, Charles S. Davis2, Komal A. Pandya1, George A. Davis1. 1University of Kentucky Medical Center, Lexington, KY, USA. 2University of Kentucky College of Pharmacy, Lexington, KY, USA


107

RETROSPECTIVE ANALYSIS OF FOUR FACTOR PROTHROMBIN COMPLEX CONCENTRATE USE IN EMERGENCY DEPARTMENT PATIENTS OVER THREE YEARS: A SINGLE CENTER EXPERIENCE
Hannah L McRae1, Ferhat Kara1, Nicole Acquisto2, Majed Refaai1. 1Department of Pathology and Laboratory Medicine, Transfusion Medicine Unit, University of Rochester Medical Center, Rochester, NY, USA. 2Departments of Pharmacy and Emergency Medicine, University of Rochester Medical Center, Rochester, NY, USA


108

VARIABILITY IN LOW MOLECULAR WEIGHT HEPARIN ANTI-XA ASSAYS BETWEEN MANUFACTURERS
Karen A Moffat1, 2, Siraj Mithoowani1, Akash Gupta1, Stephen A Carlino2, Mark A Crowther1. 1Department of Medicine, McMaster University, Hamilton, ON, Canada. 2Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada


109

SUCCESSFUL TREATMENT OF PEDIATRIC CEREBRAL VENOUSTHROMBOSIS STROKEWITH BIVALIRUDIN
Oluwaseun Olaiya, Sana Farooki, Mukta Sharma. Children's Mercy Hospital, Kansas City, MO, USA


110

THERAPEUTIC DILEMMA: MANAGING PHLEGMASIA CERULEA DOLENS IN A PEDIATRIC PATIENT WITH SEVERE CHRONIC REFRACTORY IMMUNE THROMBOCYTOPENIA
Penelope Sandiford1, Melissa Rose1, Patrick Warren2, Riten Kumar1. 1Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University, Columbus, OH, USA. 2Division of Interventional Radiology, Nationwide Children's Hospital, Department of Radiology, The Ohio State University, Columbus, OH, USA


111

INTERIM RESULTS FROM A FEASIBILITY STUDY OF THE FEARON ALGORITHM IN WARFARIN PATIENT SELF-MANAGEMENT
Daniel Witt1, Sara Vazquez1, Aubrey Jones1, John Saunders1, Paul Wegner2, Michael Fearon3. 1University of Utah, Salt Lake City, UT, USA. 2Epitome Pharmaceuticals, San Diego, CA, USA. 3Epitome Pharmaceuticals, Halifax, NS, Canada


112

CLINICAL OUTCOMES FOLLOWING ADMINISTRATION OF 4F-PCC FOR MANAGEMENT OF BLEEDING OR NEED FOR EMERGENT PROCEDURE ON A XA INHIBITOR- GOOD ENOUGH, OR DO WE NEED OTHER AGENTS?
Maura K. Wychowski, Christina I. Ruscio, Ronald L. Sham, Peter A. Kouides. Rochester General Hospital, Rochester, NY, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


113

UTILIZATION OF EMICIZUMAB AS TREATMENT IN ACQUIRED FACTOR VIII DEFICIENCY
Kevin J. Hess, Preysi Patel, Amogh M. Joshi, Adam J. Kotkiewicz. Lehigh Valley Health Network, Allentown, PA, USA


114

HEMOSTATIC EFFICACY OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE FOR REVERSAL OF APIXABAN AND RIVAROXABAN INTRACRANIAL HEMORRHAGE
John M. Koerber1, 3, Janet L. Hoffman1, 3, Sean Mertz2, Karissa Fritsch1, Nour Baalbaki3, Anant Krishnan1, Maureen A. Smythe1, 3. 1Beaumont Heatlh, Royal Oak, MI, USA. 2Cleveland Clinic, Cleveland, OH, USA. 3Wayne State University, Detroit, MI, USA


115

HEMIN USE IN PATIENTS WITH ACUTE HEPATIC PORPHYRIA TREATED WITH GIVOSIRAN: A POST HOC ANALYSIS OF THE PHASE 3 ENVISION STUDY
David Kuter 1, Sioban B. Keel 2, Laurent Gouya3, Herbert L. Bonkovsky4, Penelope E. Stein5, David C. Rees5, Samuel M. Silver 6, Charles Parker 7, Manish Thapar8, Zoe Hua9, Amy Simon 9, John J. Ko9, Petro Petrides10. 1Massachusetts General Hospital, Boston, MA, USA. 2University of Washington, Seattle, WA, USA. 3Centre Francais des Porphyries, Paris, France. 4Wake Forest University NC Baptist Health, Winston-Salem, NC, USA. 5King, London, United Kingdom. 6University of Michigan, Ann Arbor, MI, USA. 7University of Utah, Salt Lake City, UT, USA. 8Thomas Jefferson University, Philadelphia, PA, USA. 9Alnylam Pharmaceuticals, Cambridge, MA, USA. 10Hematology Oncology Center Munich, Munich, Germany

4:15 - 5:45 PM
HEMOSTASIS / LABORATORY
EVALUATING FOR BLEEDING DISORDERS: WHAT TO DO AFTER THE PATIENT WALKS THROUGH YOUR DOOR
Chair/Organizer: Salley Pells, Maria Santaella
Sheraton Ballroom 5


4:15

BLEEDING ASSESSMENT: KEY ISSUES FOR PATIENT EVALUATION FOR CLINICAL PRACTICE AND RESEARCH ACROSS THE AGE SPECTRUM.
Sarah O'Brien.


4:45

OVERVIEW ON THE LABORATORY ASSESSMENT OF PATIENTS REFERRED FOR BLEEDING PROBLEMS.
Cathy Hayward. McMaster University, Hamilton Regional Laboratory Medicine Program


5:15

NURSING PERSPECTIVES ON THE NEEDS OF PATIENTS WITH BLEEDING PROBLEMS, WITH CONSIDERATION OF THEIR QUALITY OF LIFE.
James Munn.

4:15 - 5:45 PM
BASIC SCIENCE
NEW INSIGHTS ON PLATELETS AND THEIR FUNCTIONS
Chair/Organizer: A. Koneti Rao, TBD
Chicago Ballroom 10


4:15

PLATELET THIOL ISOMERASES: BENCH TO BEDSIDE
Robert Flaumerhaft.


4:45

PLATELET-LEUKOCYTE INTERACTIONS
Matthew Rondina.


5:15

DETERMINANTS OF PLATELET HYPERREACTIVITY WITH AGING
Jorge DiPaola.

4:15 - 5:45 PM
THROMBOSIS
RISK AND BENEFITS OF COMBINATION ANTITHROMBOTIC THERAPY IN CAD: WHEN LESS IS MORE
Chair/Organizer: Eric Grabowski, Deborah Siegal
Sheraton Ballroom 1


4:15

IS THERE ANY ROLE FOR ASPIRIN IN THE TREATMENT OR PREVENTION OF VENOUS THROMBOSIS?
David Garcia. University of Washington


4:45

STABLE CAD AND PERIPHERAL ARTERIAL DISEASE: WHEN SHOULD AN ANTICOAGULANT BE CONSIDERED FOR ADDED PROTECTION
Renato Lopes.


5:15

UPDATE ON RESPONSIVENESS TO ANTIPLATELET THERAPY
Alan Michelson. Harvard Medical School

5:45 - 6:30 PM
POSTER SESSION
POSTERS/EXHIBITS
Exhibit Hall - Riverwalk AB


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


116

ANTIHEMOPHILIC FACTOR (HUMAN) CHARACTERIZATION: FOCUS ON TTP TREATMENT
Benedetta Bonito1, Cristina Genuardo1, 2, Ilaria Nardini1, Andrea Caricasole1, Claudio Farina1, Novinyo S. Amega3, Filippo Mori1. 1Department of Research a Innovation, Kedrion SpA, Via di Fondovalle, Loc. Bolognana, Italy. 2Department of Pharmacy, Pisa, Italy. 3Department of Medical Affairs, Fort Lee, NJ, USA


117

QUALITY OF LIFE AND CLINICAL OUTCOMES FROM CHESS US+: A PATIENT-CENTRIC STUDY OF SEVERE HEMOPHILIA B IN THE US
Tom Burke1, Sohaib Asghar1, Jamie O'Hara1, 2, Eileen K. Sawyer3, Nanxin (Nick) Li3. 1HCD Economics, Daresbury, United Kingdom. 2Faculty of Health and Social Care, University of Chester, Chester, United Kingdom. 3uniQure Inc, Lexington, MA, USA


118

SUBDURAL HEMORRHAGE AND CEREBRAL SINOVENOUS THROMBOSIS: FREQUENCY AND ASSOCIATIONS WITH CLINICAL AND HISTORICAL FACTORS.
Shannon L Carpenter1, Mukta Sharma1, Terra Frazier1, Lauren Beslow2, Guillaume Sebire3, Michael Noetzel4, Brian Appavu5, James D Anderst1. 1Children's Mercy Hospital, Kansas City, MO, USA. 2Children's Hospital of Philadelphia, Philadelphia, PA, USA. 3Montreal Children Hospital, Montreal, QC, Canada. 4Washington University, St. Louis, MO, USA. 5Phoenix Children's Hospital, Phoenix, AZ, USA


119

CLINICAL VALIDATION OF THE HAEMO-QOL-A AFTER VALOCTOCOGENE ROXAPARVOVEC TREATMENT: RESULTS FROM 2 STUDIES
Jennifer Quinn1, Nina Mitchell1, Wing Yen Wong2, Wolfgang Miesbach3, Monika Bullinger4, Kathleen A. Delaney2. 1BioMarin Pharmaceutical, Inc, London, United Kingdom. 2BioMarin Pharmaceutical, Inc, Novato, CA, USA. 3Universitats Klinikum Frankfurt, Medical Clinic 2, Goethe Universitat, Frankfurt, Germany. 4Department of Medical Psychology, University Medical Center Hamburg Eppendorf, Hamburg, Germany


120

IDENTIFICATION AND CHARACTERIZATION OF A NOVEL THROMBOMODULIN LECTIN-LIKE DOMAIN VARIANT IN A PATIENT WITH VENOUS THROMBOSIS
Sean X. Gu1, Lauren M. Shevell2, Christopher A. Tormey1, Henry M. Rinder1, Noffar Bar2, 3, Alfred I. Lee2, 3. 1Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA. 2Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. 3Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA


122

HIGH-PURITY PLASMA-DERIVED FACTOR X IS EFFECTIVE FOR SHORT-TERM PREVENTATIVE USE AND PERI-SURGICAL HEMOSTATIC COVER: RESULTS FROM A RETROSPECTIVE, OPEN-LABEL, COMPASSIONATE-USE STUDY OF PATIENTS WITH HEREDITARY FACTOR X DEFICIENCY
Martina Buehrlen1, Tiraje Celkan2, James N Huang3, Chioma Akanezi4, Sarale Russ4. 1Klinikum Bremen-Mitte, Prof-Hess-Kinderklinik, Bremen, Germany. 2Istanbul University Cerrahpasa School of Medicine, Fatih, Istanbul, Turkey. 3University of California San Francisco, Benioff Children, San Francisco, CA, USA. 4Bio Products Laboratory Ltd, Elstree, United Kingdom


123

AN IDENTIFIED MUTATIONAL HOTSPOT IN TWO DIFFERENT EXONS OF FIBRINOGEN ALPHA GENE OF CONGENITAL FIBRINOGEN DEFICIENT PATIENTS. BACKGROUND: INHERITED FIBRINOGEN DEFICIENCY IS TRANSMITTED AS AN AUTOSOMAL RECESSIVE DISEASE WITH AN ABSENT LEVEL OF ACTIVATED FIBRINOGEN PROTEIN IN PLASMA. THIS DISORDER HAS MANIFESTED ITS STRONG ASSOCIATION WITH COUSIN MARRIAGE IN OUR SET OF POPULATION WITH SWIFTLY INCREASING NO. OF NEW CASES EACH YEAR. AIM: TO SEARCH OUT FOR SPECTRUM OF MUTATION IN PREVIOUSLY IDENTIFIED MUTATIONS DETECTED IN ALL THREE GENES OF FIBRINOGEN (FGA ALPHA, BETA AND GAMMA) METHODS: THIS DESCRIPTIVE CROSS SECTIONAL STUDY IN CONCORDANCE WITH DECLARATION OF HELSINKI 2000 WAS CONDUCTED IN KARACHI, PAKISTAN. ALL DIAGNOSED CASES OF INHERITED FACTOR 1 DEFICIENCY WERE INCLUDED. RESULTS: TOTAL 14 PATIENTS WERE INCLUDED IN THIS STUDY. OUT OF 14 PATIENTS, 5 WERE SHOWN TO HAVE SIMILAR NONSENSE MUTATION IN EXON 4 AND SIX SAME MISSENSE MUTATION IN EXON 5 OF FIBRINOGEN ALPHA GENE. THIS GENE IS ALSO REPORTED AS THE MOSTLY FREQUENTLY AFFECTED GENE WITH LARGER NO. OF IDENTIFIED MUTATIONS IN GLOBAL RESEARCH DATA. CONCLUSION: RARITY OF INHERITED FACTOR 1 ABSENCE IS DEBATABLE NOW DUE TO ITS SWIFTLY INCREASING INCIDENCE ESPECIALLY IN OUR REGION WHERE COUSIN MARRIAGES ARE ACCUSTOMED. ALTHOUGH FIBRINOGEN GAMMA GENE IS THE LARGEST AMONGST ALL THREE GENES OF FIBRINOGEN PROTEIN WITH 10 EXONS BUT SPECTRUM OF MUTATIONS IN FIBRINOGEN ALPHA GENE HAS PROVEN ITS FREQUENT INVOLVEMENT AND RECOGNIZED AS A MAJOR CONTRIBUTOR IN CAUSING AND EXHIBITING MANIFESTATION OF DISEASE. DISCLOSURE OF INTEREST: NONE DECLARED. KEY WORDS: SPECTRUM OF MUTATION, INHERITED BLEEDING DIATHESIS, CONSANGUINITY, FACTOR 1 DEFICIENCY, FIBRINOGEN PROTEIN
Tehmina Khan1, Arshi Naz1, Anne Goodeve2, Shariq Ahmed1, Tahir Shamsi1, johannes Oldenburg3. 1NIBD, Karachi, Pakistan. 2University of Sheffield, sheffield, United Kingdom. 3Institute of experimental transfusions Medicine, Bonn, Germany


124

ACQUIRED HEMOPHILIA: CLINICAL CHARACTERISTICS AND BLEEDING OUTCOMES
Rohit Kumar1, Shruti Bhandari1, Sunny Singh2, Sindhu Malapati3. 1University of Louisville, Louisville, KY, USA. 2Henry Ford Cancer Institute, Detroit, MI, USA. 3Ascension St. John Hospital and Medical Center, Detroit, MI


125

POPULATION PHARMACOKINETICS OF RECOMBINANT VON WILLEBRAND FACTOR IN PATIENTS WITH VON WILLEBRAND DISEASE OR SEVERE HEMOPHILIA A
Alexander Bauer1, Bettina Ploder1, Zhaoyang Li2, Bjorn Mellgard3, Sofia Friberg-Hietala4, Martin Wolfsegger1. 1Baxalta Innovations GmbH, a Takeda company, Vienna, Austria. 2Shire US Inc, a Takeda company, Cambridge, MA, USA. 3Baxalta US Inc, a Takeda company, Cambridge, MA, USA. 4Pharmetheus AB, Uppsala, Sweden


126

NOVEL PRENATAL DIAGNOSIS OF PROTEIN C DEFICIENCY AND PRIMARY PROPHYLAXIS WITH PROTEIN C CONCENTRATE: A CASE SERIES.
Alexandra Prosser, Lauren Amos, Mukta Sharma. Children's Mercy Hospital, Kansas City, MO, USA


127

LONG-TERM BLEEDING AND CONSUMPTION RATES OF PROPHYLAXIS WITH BAY 94-9027 IN ADOLESCENTS AND YOUNG ADULTS WITH HEMOPHILIA A IN THE PROTECT VIII STUDY
Sanjay Ahuja1, Mindy L. Simpson2, Jonathan M. Ducore3, Olubunmi Afonja4, Inga Bayh5, Mark T. Reding6. 1Rainbow Babies a Children, Cleveland, OH, USA. 2Rush University Medical Center, Chicago, IL, USA. 3University of California Davis Medical Center, Sacramento, CA, USA. 4Bayer, Whippany, NJ, USA. 5Bayer, Wuppertal, Germany. 6University of Minnesota Medical Center, Minneapolis, MN, USA


A8. ANTITHROMBOTIC THERAPY


128

DESCRIBING THE USE OF COAGULATION FACTOR XA (RECOMBINANT), INACTIVATED-ZHZO (ANDEXANET ALFA) AT A MULTICENTER HEALTH SYSTEM
Krishna Modi, Dana Attar, Philip Kuriakose , Jona Lekura, Gerald Koenig, Long To, Michael Hudson, Panayiotis Mitsias , Abdul-Nasser Charara, James Kalus, Norm Buss, Mohammed Rehman, Scott Kaatz. Henry Ford Health System, Detroit, MI, USA


129

TITLE: FIXED-DOSE 1500 UNIT 4F-PCC FOR APIXABAN OR RIVAROXABAN REVERSAL IN MAJOR BLEEDING
Jamie Kooiman, Sean Lujan, Lisa Anselmo, Mindy Mason, Chelsea Rodriguez, Allison Burnett. University of New Mexico Hospital, Albuquerque, NM, USA


130

SHORT-TERM OUTCOMES OF CATHETER-RELATED ARTERIAL THROMBOSIS IN NEONATES AND CHILDREN
Clay T Cohen1, 2, Viia Anderson1, 2, Kristen A Staggers1, Rosa Diaz1, 2. 1Baylor College of Medicine, Houston, TX, USA. 2Texas Children's Hematology and Cancer Centers, Houston, TX, USA


131

BUNDLE APPROACH IN VENOUS THROMBOEMBOLISM PROPHYLAXIS IN PATIENTS WITH NON-TRAUMATIC SUBARACHNOID HEMORRHAGE
Brian V. Phan1, Keri S. Kim2. 1University of California, Los Angeles Health, Los Angeles, CA, USA. 2University of Illinois Health, Chicago, IL, USA


132

UTILIZATION OF APIXABAN AND RIVAROXABAN LEVELS IN CLINICAL PRACTICE
Anne E Rose1, Erin N Robinson1, Cameron J Patterson1, Katherine A Cinnamon1, David J Ciske2. 1UW Health, Madison, WI, USA. 2University of Wisconsin Medical Foundation, Madison, WI, USA


133

DEVELOPMENT AND IMPLEMENTATION OF A SYSTEM BASED INTERVENTION FOR HEALTHCARE-ASSOCIATED VENOUS THROMBOEMBOLISM PROPHYLAXIS AT A SAFETY NET ACADEMIC MEDICAL CENTER
Alyssa E. Utz1, Michael Knauss1, Palak K. Patel1, Mikhail Y. Akbashev2. 1Grady Health System, Atlanta, GA, USA. 2Emory University School of Medicine, Atlanta, GA, USA


134

THE USE OF UNFRACTIONATED HEPARIN (UFH) VERSUS LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN HOSPITALIZED PATIENT WITH ACUTE DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE)
Steven J. Jubelirer1, Talia E. Alexander1, Christine A. Welch2. 1Charleston Area Medical Center/West Virginia University, Charleston, WV, USA. 2Charleston Area Medical Center/ Outcomes Research, Charleston, WV, USA


135

SEROPREVALENCE OF PRE-EXISTING NABS AGAINST AAV1, 2, 5, 6 AND 8 IN A SOUTH AFRICAN HEMOPHILIA PATIENT POPULATION
Anna Majowicz1, Nolukholo Ncete2, Floris van Waes1, Nikki Timmer1, Sander J van Deventer1, Johnny N Mahlangu2, Valerie Ferreira1. 1uniQure B. V, Amsterdam, Netherlands. 2Hemophilia Comprehensive Care Center, Johannesburg, South Africa


136

PREVALENCE AND AFFINITY/AVIDITY ASSESSMENT OF PRE-EXISTING NABS AGAINST AAV1, 2, 5, AND 8, ANALYZED IN THE SERUM OF 300 HEALTHY DONORS
Anna Majowicz, Floris van Waes, Nikki Timmer, Sander J van Deventer, Valerie Ferreira. uniQure B. V, Amsterdam, Netherlands


137

RECENT PROGRESS IN THE DEVELOPMENT PROGRAM OF AMT-061 (ETRANACOGENE DEZAPARVOVEC) FOR PERSONS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B
Steven W Pipe1, Wolfgang Miesbach2, Annette Von Drygalski3, Adam Giermasz4, Karina Meijer5, Michiel Coppens6, Peter Kampmann7, Robert Klamroth8, Roger Schutgens9, Nigel S Key10, Susan Lattimore11, Michael Recht11, Esteban Gomez13, Giancarlo Castaman14, Eileen K Sawyer12, Robert Gut12. 1University of Michigan, Ann Arbor, MI, USA. 2University Hospital Frankfurt, Frankfurt, Germany. 3University of California San Diego, San Diego, CA, USA. 4University of California Davis, Sacramento, CA, USA. 5University Medical Center Groningen, Groningen, Netherlands. 6Academic Medical Center, Amsterdam, Netherlands. 7Rigshospitalet, Copenhagen, Denmark. 8Vivantes Klinikum, Berlin, Germany. 9University Medical Center, Utrecht, Netherlands. 10University of North Carolina, Chapel Hill, NC, USA. 11Oregon Health a Science University, Portland, OR, USA. 12uniQure biopharma B. V, Lexington, MA, USA. 13Phoenix Children's Hospital, Phoenix, AZ, USA. 14Azienda Ospedaliera Universitaria Careggi, Florence, Italy. 15Erasmus University Medical Center, Rotterdam, Netherlands


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


138

PATIENT SATISFACTION WITH HEMOPHILIA TREATMENT CENTERS: DIFFERENCES BETWEEN MILDS AND SEVERES FROM THE 2ND NATIONAL US HTC PATIENT SATISFACTION SURVEY
Judith Baker1, 2, Rick Shearer3, Merilee Ashton3, Susan Lattimore4. 1Center for Inherited Blood Disorders, Orange, CA, USA. 2UCLA, Los Angeles, CA, USA. 3University of Colorado, Aurora, CO, USA. 4Oregon Health a Science University, Portlant, OR, USA

6:30 - 8:30 PM
SATELLITE SYMPOSIUM
GENENTECH DINNER SYMPOSIA: GET YOUR GAME ON: HEMOPHILIA A EDITION
Chicago Ballroom 7


SANOFI GENZYME DINNER SYMPOSIA: BEYOND ABRS: HCP AND PATIENT PERSPECTIVES IN AN EVOLVING HEMOPHILIA TREATMENT LANDSCAPE
Chicago Ballroom 6